Gilead Sciences, Inc. GILD

NASDAQ · Healthcare · Drug Manufacturers - General

$166.43

Close on Fri, 20 Nov 2026 · market value $206B

What the price is betting on

Below its record

At $166, the price assumes revenue shrinks about 5.5% a year for five years, from $31B to about $24.4B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−5.5%
Analysts, next two years5.4%
Last 3 years5%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.9% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than GILD? Check up to 5 of your stocks at once, free, no account.

0$10B$20B$30B$40B$31B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$283

Base

$323

Bull

$369

Today $166

  • Bear $283. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $323. Cash flow grows 6% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $369. Cash flow grows 8% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$30.6B$31.3B, on the path
  3. FY2027$28.9B$33.6B, on the path
  4. FY2028$27.3B$34.7B, on the path
  5. FY2029$25.8B$37.3B, on the path
  6. FY2030$24.4B$39.6B, on the path

Each year's revenue at −5.5% growth from $31B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - General · listed on NASDAQ

Revenue, FY2025
$29.4B
Growth, 3 years a year
5%
Cash margin
32%
Net debt
$15.3B
Shares, 3-year change
−0.6%
Dividend yield
1.9%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.